



## **Tanvex filed response to Amgen's lawsuit**

Sep. 24, 2019

Today, Tanvex BioPharma, Inc., and its wholly owned subsidiaries, Tanvex Biologics Corporation and Tanvex BioPharma USA, Inc., filed a response to Amgen's complaint for patent infringement in the United States District Court for the Southern District of California. Tanvex's response included defenses and counterclaims of non-infringement and invalidity.

As background, on July 23, 2019, Amgen filed lawsuit against Tanvex in the United States alleging infringement of U.S. Patent No. 9,856,287 (the '287 patent) based on Tanvex's submission of a Biologics License Application (BLA) for TX01 to the United States Food and Drug Administration. TX01 is a proposed biosimilar to Neupogen® (filgrastim).

### **About Tanvex**

Tanvex BioPharma, Inc. (TWSE: 6541) is a biopharmaceutical company focused on the biosimilar market. The Company is vertically integrated with end-to-end in-house development, manufacturing and commercialization capabilities. Tanvex BioPharma, Inc. is registered in Cayman Islands and has operations and facilities in Irvine, CA, San Diego, CA, and Taipei, Taiwan. Tanvex is publicly traded on the Taiwan Stock Exchange.